UNSPSC 51451603: Fenbendazole

This classification denotes an antihelminthic agent with the molecular formula C15H13N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 621BVT9M36, chemically known as 2-benzimidazolecarbamic acid, 5-(phenylthio)-, methyl ester but generally known as fenbendazole, which bears US NIH Compound Identifier 3334. European Medicines Agency schedules Fenbendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07541MIG.

UNSPSC 51451603 Fenbendazole, a Commodity code, shows minimal alignment between its nominal scope and recent state and local contract activity. The code nominally addresses a single veterinary anthelmintic pharmaceutical, yet the recent opportunities posted under this code bracket state and local procurement for naloxone, drug deactivation systems, emergency medical supplies, and generic multi-source pharmaceuticals—none of which are fenbendazole. The mismatch suggests either tagging inconsistency in the source system or that fenbendazole itself generates little recent state and local solicitation activity. The few posted opportunities span health departments, fire rescue divisions, and cooperative purchasing alliances, indicating fragmented issuing-body participation rather than concentrated demand from a particular jurisdiction type or sector.

Recent opportunities include Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems through a competitive bidding process; the City of Tampa's IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for medical and first aid supplies to the Fire Department Rescue Division, with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside with a 5 percent bid discount; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) for direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. Geographic activity centers on Florida, Texas, and Minnesota, with the cooperative purchasing vehicle (MMCAP) serving multiple states including Oregon. The code does not demonstrate sustained or consolidated demand for fenbendazole specifically and warrants verification against the issuing body's actual procurement specifications before pursuit.